Increased amyloid β-peptide uptake in skeletal muscle is induced by hyposialylation and may account for apoptosis in GNE myopathy

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13354-13371

  Bosch Morató, Mònica ^a   Iriondo, Cinta ^a   Guivernau, Biuse ^a   Valls Comamala, Victòria ^a   Vidal, Noemí ^b   Olivé, Montse ^b   Querfurth, Henry ^c   Muñoz, Francisco J ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c BROWN UNIVERSITY   (United States)

Author keywords

Akt; Apoptosis; A ; Endocytosis; Gerotarget; GNE myopathy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CLATHRIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PROTEIN KINASE B; PROTEOHEPARAN SULFATE; AMYLOID BETA PROTEIN; N ACETYLNEURAMINIC ACID;

ADULT; APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CALCIUM TRANSPORT; CASE REPORT; CELL DEATH; CLATHRIN DEPENDENT ENDOCYTOSIS; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; GNE MYOPATHY; HUMAN; HUMAN CELL; HYPOSIALYLATION; INTERNALIZATION; MYOBLAST; MYOPATHY; MYOTUBE; PROTEIN AGGREGATION; PROTEIN TRANSPORT; SIALYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; CASE CONTROL STUDY; CELL CULTURE; DISTAL MYOPATHY; MALE; METABOLISM; PATHOLOGY; SKELETAL MUSCLE CELL;

ADULT; AMYLOID BETA-PEPTIDES; APOPTOSIS; CASE-CONTROL STUDIES; CELLS, CULTURED; DISTAL MYOPATHIES; FEMALE; HUMANS; MALE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOBLASTS; N-ACETYLNEURAMINIC ACID;

EID: 84971597912     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7997     Document Type: Article

References (52)

1. Dickson DW. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging. 1997; 18:S21-26.
2. Gouras GK, Almeida CG, and Takahashi RH. Intraneuronal AB accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging. 2005; 26:1235-1244.
3. Broccolini A, Gidaro T, Morosetti R, and Mirabella M. Hereditary inclusion-body myopathy: clues on pathogenesis and possible therapy. Muscle Nerve. 2009; 40:340-349.
4. Askanas V, Engel WK, and Alvarez RB. Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology. 1993; 43:1265-1267.
5. Argov Z, and Yarom R. "Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews. J Neurol Sci. 1984; 64:33-43.
6. Askanas V, and Engel WK. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 2011; 40:e219-235.
7. Nishino I, Noguchi S, Murayama K, Driss a, Sugie K, Oya Y, Nagata T, Chida K, Takahashi T, Takusa Y, Ohi T, Nishimiya J, Sunohara N, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology. 2002; 59:1689-1693.
8. Argov Z, Eisenberg I, and Mitrani-Rosenbaum S. Genetics of inclusion body myopathies. Curr Opin Rheumatol. 1998; 10:543-547.
9. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardini G, Shmilevich I, Friedmann A, Karpati G, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 2001; 29:83-87.
10. Eisenberg I, Grabov-Nardini G, Hochner H, Korner M, Sadeh M, Bertorini T, Bushby K, Castellan C, Felice K, Mendell J, Merlini L, Shilling C, Wirguin I, et al. Mutations spectrum of GNE in hereditary inclusion body myopathy sparing the quadriceps. Hum Mutat. 2003; 21:99-105.
11. Schwarzkopf M, Knobeloch K-P, Rohde E, Hinderlich S, Wiechens N, Lucka L, Horak I, Reutter W, and Horstkorte R. Sialylation is essential for early development in mice. Proc Natl Acad Sci U S A. 2002; 99:5267-5270.
12. Hinderlich S, Stäsche R, Zeitler R, and Reutter W. A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat live. Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. J Biol Chem. 1997; 272:24313-24318.
13. Schauer R. Sialic acids: fascinating sugars in higher animals and man. Zool. 2004; 107:49-64.
14. Effertz K, Hinderlich S, and Reutter W. Selective loss of either the epimerase or kinase activity of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase due to site-directed mutagenesis based on sequence alignments. J Biol Chem. 1999; 274:28771-28778.
15. Gagiannis D, Orthmann A, Danssmann I, Schwarzkopf M, Weidemann W, and Horstkorte R. Reduced sialylation status in UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE)-deficient mice. Glycoconj J. 2007; 24:125-130.
16. Noguchi S, Keira Y, Murayama K, Ogawa M, Fujita M, Kawahara G, Oya Y, Imazawa M, Goto Y-I, Hayashi YK, Nonaka I, and Nishino I. Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J Biol Chem. 2004; 279:11402-11407.
17. Malicdan MC V, Noguchi S, Nonaka I, Hayashi YK, and Nishino I. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Hum Mol Genet. 2007; 16:2669-2682.
18. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol. 2009; 19:507-514.
19. Malicdan MC V, Noguchi S, Hayashi YK, Nonaka I, and Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med. 2009; 15:690-695.
20. Wilson CA, Doms RW, and Lee VM. Intracellular APP processing and A beta production in Alzheimer disease. J Neuropathol Exp Neurol. 1999; 58:787-794.
21. Hartmann T, Bieger SC, Brühl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, and Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med. 1997; 3:1016-1020.
22. Koo EH, and Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994; 269:17386-17389.
23. Sandwall E, O'Callaghan P, Zhang X, Lindahl U, Lannfelt L, and Li J-P. Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology. 2010; 20:533-541.
24. Kanekiyo T, and Bu G. Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. J Biol Chem. 2009; 284:33352-33359.
25. Sakono M, and Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010; 277:1348-1358.
26. Muñoz FJ, and Inestrosa NC. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett. 1999; 450:205-209.
27. Soto C, Castaño EM, Frangione B, and Inestrosa NC. The alfa-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem. 1995; 270:3063-3067.
28. Wisniewski T, Ghiso J, and Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun. 1991; 179:1247-1254.
29. Ryder J, Su Y, and Ni B. Akt/GSK3β serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell Signal. 2004; 16:187-200.
30. Magrané J, Rosen KM, Smith RC, Walsh K, Gouras GK, and Querfurth HW. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J Neurosci. 2005; 25:10960-10969.
31. Lee H-K, Kumar P, Fu Q, Rosen KM, and Querfurth HW. The Insulin/Akt Signaling Pathway Is Targeted by Intracellular B-Amyloid. Mol Biol Cell. 2009; 20:1533-1544.
32. Szado T, Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, Kotelevets L, Chastre E, Khan F, Landegren U, Söderberg O, Bootman MD, and Roderick HL. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci U S A. 2008; 105:2427-2432.
33. Marchi S, Rimessi A, Giorgi C, Baldini C, Ferroni L, Rizzuto R, and Pinton P. Akt kinase reducing endoplasmic reticulum Ca2+ release protects cells from Ca2+-dependent apoptotic stimuli. Biochem Biophys Res Commun. 2008; 375:501-505.
34. Marchi S, Marinello M, Bononi A, Bonora M, Giorgi C, Rimessi A, and Pinton P. Selective modulation of subtype III IP3R by Akt regulates ER Ca2+ release and apoptosis. Cell Death Dis. 2012; 3:e304.
35. Supnet C, and Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium. 2010; 47:183-189.
36. Henning RH, Duin M, van Popta JP, Nelemans A, and den Hertog A. Different mechanisms of Ca2(+)-handling following nicotinic acetylcholine receptor stimulation, P2U-purinoceptor stimulation and K(+)-induced depolarization in C2C12 myotubes. Br J Pharmacol. 1996; 117:1785-1791.
37. Askanas V, and Engel WK. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol. 1998; 10:530-542.
38. Williamson MP, Suzuki Y, Bourne NT, and Asakura T. Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13. Biochem J. 2006; 397:483-490.
39. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, and Yanagisawa K. A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem. 2007; 282:2646-2655.
40. Kumamoto T, Abe T, Nagao S, Ueyama H, and Tsuda T. Immunohistochemical study of clathrin in distal myopathy with rimmed vacuoles. Acta Neuropathol. 1998; 95:571-575.
41. Nishitsuji K, Hosono T, Uchimura K, and Michikawa M. Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes. J Biol Chem. 2011; 286:6393-6401.
42. Querfurth HW, Suhara T, Rosen KM, McPhie DL, Fujio Y, Tejada G, Neve RL, Adelman LS, and Walsh K. Beta-amyloid peptide expression is sufficient for myotube death: implications for human inclusion body myopathy. Mol Cell Neurosci. 2001; 17:793-810.
43. Amsili S, Shlomai Z, Levitzki R, Krause S, Lochmuller H, Ben-Bassat H, and Mitrani-Rosenbaum S. Characterization of hereditary inclusion body myopathy myoblasts: possible primary impairment of apoptotic events. Cell Death Differ. 2007; 14:1916-1924.
44. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, and Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997; 275:661-665.
45. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, and Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998; 282:1318-1321.
46. Suhara T, Magrané J, Rosen K, Christensen R, Kim HS, Zheng B, McPhie DL, Walsh K, and Querfurth H. Aβ42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3β signaling-dependent mechanism. Neurobiol Aging. 2003; 24:437-451.
47. Demuro A, and Parker I. Cytotoxicity of intracellular aβ42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. J Neurosci. 2013; 33:3824-3833.
48. Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, and Alkon DL. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1994; 91:534-538.
49. Shtifman A, Ward CW, Laver DR, Bannister ML, Lopez JR, Kitazawa M, LaFerla FM, Ikemoto N, and Querfurth HW. Amyloid-β protein impairs Ca2+ release and contractility in skeletal muscle. Neurobiol Aging. 2010; 31:2080-2090.
50. Malicdan MC V, Noguchi S, Tokutomi T, Goto Y, Nonaka I, Hayashi YK, and Nishino I. Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy. J Biol Chem. 2012; 287:2689-2705.
51. Ito M, Sugihara K, Asaka T, Toyama T, Yoshihara T, Furuichi K, Wada T, and Asano M. Glycoprotein hyposialylation gives rise to a nephrotic-like syndrome that is prevented by sialic acid administration in GNE V572L point-mutant mice. PLoS One. 2012; 7:e29873.
52. Coma M, Guix FX, Ill-Raga G, Uribesalgo I, Alameda F, Valverde MA, and Muñoz FJ. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol Aging. 2008; 29:969-980.